Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, showed manageable safety and efficacy for pretreated non-small cell lung cancer and esophageal squamous cell carcinoma [45, 46]. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.